Wednesday, February 10, 2010, 12:47am EST - Canadian Markets open in 8 hours and 43 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Trimeris Inc. (TRMS)

 On Feb 9: 2.35 USD  Up 0.05 (2.17%)  
MORE ON TRMS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Trimeris, Inc. (NGM:TRMS) Delayed quote dataEdit
Last Trade: 2.35 USD
Trade Time: Feb 9
Change: Up 0.05 (2.17%)
Prev Close: 2.30
Open: 2.35
Bid: 1.44 x 100
Ask: 2.45 x 200
1y Target Est: 1.40
Day's Range: 2.35 - 2.42
52wk Range: 1.01 - 3.68
Volume: 19,394
Avg Vol (3m): 202,513
Market Cap: 52.52M
P/E (ttm): 7.97
EPS (ttm): 0.30
Div & Yield: N/A (N/A%)
Trimeris Inc. (TRMS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add TRMS to Portfolio   Download Data

HEADLINES
• TRIMERIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Wed, Feb 3)
• Trimeris Reports Fourth Quarter 2009 FUZEON® Sales Results
Business Wire (Tue, Feb 2)
• TRIMERIS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
EDGAR Online (Mon, Jan 11)
• Trimeris Receives Delisting Notice From NASDAQ
Business Wire (Mon, Jan 11)
• CSI: Trimeris-Arigene
at The New York Times (Mon, Jan 11)
• TRIMERIS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
EDGAR Online (Tue, Jan 5)
• Pfizer Discontinues Cancer Drug: Biotech's Recently Missed Targets
at Seeking Alpha (Mon, Jan 4)
• TRIMERIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Dec 29)
• CBL & Associates Properties, Trimeris: Biggest Price Decliners (CBL, TRMS)
at The Wall Street Journal Online (Tue, Dec 29)
• Biotech Stocks: Drug stocks slip; Trimeris falls on failed merger
at MarketWatch (Tue, Dec 29)
• Korean medical product maker ends bid for Trimeris
AP (Tue, Dec 29)
More Headlines for TRMS...
ANALYST
EPS Est (next year) (Dec-09) : N/A
EPS Est (in 2 years) (Dec-10) : N/A
Avg Rec (current)*: 3.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetra...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices